STOCK TITAN
  1. Home
  2. News
  3. REGN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated news page for Regeneron Pharmaceuticals (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regeneron Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regeneron Pharmaceuticals's position in the market.

News
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. presents positive pivotal data on linvoseltamab for relapsed/refractory multiple myeloma at AACR Annual Meeting 2024. The data show promising results with high response rates, durable responses, and good safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
News
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) will report its Q1 2024 financial results on May 2, 2024. A conference call and webcast will be held at 8:30 AM Eastern Time. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences earnings
-
News
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Rhea-AI Summary
SillaJen submits CSR to the US FDA for REN026, a study on Pexa-Vec and cemiplimab in RCC patients. The study shows positive safety and efficacy results, with high response rates and overall survival. Collaboration with Regeneron Pharmaceuticals yields promising outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
News
Regeneron Provides Update on Biologics License Application for Odronextamab
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. receives Complete Response Letters from the FDA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma due to enrollment status issues in confirmatory trials. Despite this, no concerns were raised regarding clinical efficacy, safety, design, labeling, or manufacturing. Regeneron is actively enrolling patients in Phase 3 trials as part of the OLYMPIA program, aiming to revolutionize B-cell non-Hodgkin lymphoma treatment. The company is dedicated to collaborating with the FDA to expedite the availability of odronextamab for patients. Updates on enrollment and regulatory timelines are expected later this year, while EMA review continues for R/R DLBCL and R/R FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Rhea-AI Summary
Achyuta Rajaram, 17, from Exeter, NH, wins the top award of $250,000 in the Regeneron Science Talent Search 2024. The competition, in its 83rd year, highlights young innovators in STEM fields. Other winners include Thomas Cong and Michelle Wei.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
-
News
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA approval to extend the use of Praluent for children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows Praluent to be used as an adjunct to diet and other LDL-C lowering therapies, providing a new treatment option for children with high LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
fda approval
News
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces positive results for EYLEA HD in treating wet age-related macular degeneration and diabetic macular edema. The Lancet published one-year data from PULSAR and PHOTON trials showing non-inferior vision gains with extended dosing regimens compared to standard care. EYLEA HD offers durable visual improvements, fluid control, and reduced treatment burden for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
News
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi's Dupixent granted Priority Review by FDA for potential COPD indication based on positive Phase 3 trial results, aiming to be the only biologic therapy for COPD and the first new treatment approach in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
-
News
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA Priority Review for linvoseltamab to treat relapsed/refractory multiple myeloma. The BLA is supported by Phase 1/2 trial data, with a target action date of August 22, 2024. Linvoseltamab aims to activate T cells for cancer-cell killing in MM patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
News
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi receive approval in Japan for Dupixent to treat chronic spontaneous urticaria, expanding its indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
Stock REGN logo
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

#121 Ranked by Market Cap
#1795 Ranked by Stock Gains
N/A Ranked by Dividends

REGN Stock Data

99.30B
102.75M
2.58%
89.25%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tarrytown

About REGN

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.